Avandia to Remain on the Market– For NowPublished by John Hopkins in Mass Torts, Product Defect
The FDA panel of 33 medical experts recommended that Avandia remain on the market. This decision was made even though Avandia and the clinical trials conducted about the drug are shrouded in suspicion and doubts about the impartiality of results.
The FDA panel, however, was anything but unanimous. Only 17 members voted in favor o fallowing Avandia to remain on the market, but requiring additional “black box” warnings about the drug. . This successfully permits Avandia to remain on the market for use in the treatment of diabetes. Three experts wanted to, essentially, do nothing and allow Avandia to remain on the market without further warnings. A dozen of the medical experts voted to recall Avandia.
The FDA can choose to follow the recommendations or can choose to take other action; the committee’s recommendations are not binding.
For now, if you are taking Avandia, consult with your physician regarding the decision to stay on the drug. Never discontinue taking a drug without first consulting with your physician and getting their advice.